Ankasa Regenerative Therapeutics
Sanford J. Madigan is the CEO at Ankasa Regenerative Therapeutics.
This person is not in any offices
Ankasa Regenerative Therapeutics
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.